Celltrion Inc

Celltrion Inc

068270 · KO · Healthcare / Biotechnology

213,000.00KRW-2000.00 (-0.93%)

Price History

Full chart

Market Stats

Previous Close215,000.00
Open211,000.00
Day Range211,000.00 – 216,500.00
52-Week Range158,500.00 – 239,047.63
Volume574.74K
Market Cap48.80T
P/E (TTM)30.31
Forward P/E27.62
EPS6,912.14
Dividend Yield0.34%
Beta0.23
50-Day Avg188,344.00
200-Day Avg190,138.03

About

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Woo-Sung Kee
  • Employees2.96K
  • Headquarters23, Academy-ro, Incheon, South Korea, Korea
  • Websitehttps://www.celltrion.com

Leadership

  • Mr. Woo-Sung KeeCo-CEO & Internal Director · b. 1961
  • Mr. Jin-Seok SeoCo-CEO & Inside Co-Chairman of the Board · b. 1984
  • Mr. Stephen YeumFounder
  • Mr. Min-Cheol ShinCFO, Director of Finance & Inside Director · b. 1971
  • Mr. Ji-Hoon ChoiDirector of Legal Affairs · b. 1971

Financials

Income Statement

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue60.08B83.69B145.55B180.95B279.04B350.20B226.21B471.05B603.41B670.58B949.08B982.07B1.13T1.85T1.91T2.28T2.18T3.56T4.16T
Growth (%)-+39.29%+73.92%+24.32%+54.21%+25.50%-35.41%+108.24%+28.10%+11.13%+41.53%+3.48%+14.91%+63.86%+3.38%+19.48%-4.71%+63.45%+17.01%
Cost of Revenue50.86B36.14B51.59B39.43B52.26B93.91B68.69B129.91B234.57B273.98B251.25B431.17B494.97B821.45B805.81B1.25T1.12T1.88T1.70T
Gross Profit9.23B47.55B93.96B141.52B226.78B256.28B157.52B341.14B368.84B396.60B697.83B550.91B633.49B1.03T1.11T1.03T1.05T1.68T2.47T
Gross Margin15.35%56.82%64.55%78.21%81.27%73.18%69.64%72.42%61.13%59.14%73.53%56.10%56.14%55.58%57.85%45.22%48.33%47.27%59.27%
Operating Expense7.58B16.78B22.21B34.90B47.47B60.83B57.68B139.67B109.89B146.91B198.25B227.78B251.96B309.09B348.94B385.50B400.39B1.19T1.31T
Operating Income1.65B30.77B71.75B106.62B179.31B195.45B99.85B201.47B258.95B249.69B499.59B323.13B381.53B718.58B756.86B647.20B651.48B492.02B1.16T
Operating Margin2.75%36.77%49.30%58.92%64.26%55.81%44.14%42.77%42.91%37.24%52.64%32.90%33.81%38.86%39.59%28.34%29.93%13.83%27.78%
EBITDA6.34B17.35B81.78B125.91B202.96B241.44B197.64B263.84B329.99B348.23B596.96B443.89B545.78B840.51B998.78B873.17B926.59B1.07T1.52T
EBITDA Margin10.56%20.73%56.19%69.59%72.73%68.94%87.37%56.01%54.69%51.93%62.90%45.20%48.37%45.45%52.25%38.23%42.57%30.08%36.44%
Net Income2.29B14.57B58.54B108.37B167.81B174.43B102.45B112.68B154.09B177.99B368.22B245.76B301.03B517.76B579.46B537.84B535.65B422.69B1.03T
Net Income Margin3.81%17.41%40.22%59.89%60.14%49.81%45.29%23.92%25.54%26.54%38.80%25.02%26.68%28.00%30.31%23.55%24.61%11.88%24.74%
R&D771.86M3.31B5.76B16.14B19.15B31.09B25.39B69.64B37.32B65.36B79.66B108.06B113.57B171.44B125.77B139.71B161.11B199.72B210.70B
R&D as % of Total Revenue1.28%3.95%3.96%8.92%6.86%8.88%11.22%14.78%6.18%9.75%8.39%11.00%10.06%9.27%6.58%6.12%7.40%5.61%5.06%
Interest Expense1.23B6.62B2.46B1.07B2.60B16.82B32.12B38.35B29.71B14.09B14.67B14.75B10.83B7.50B8.24B7.51B9.67B75.57B75.47B
Interest Expense % of Total Revenue2.04%7.91%1.69%0.59%0.93%4.80%14.20%8.14%4.92%2.10%1.55%1.50%0.96%0.41%0.43%0.33%0.44%2.12%1.81%

Balance Sheet

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets61.46B499.26B559.20B1.16T1.41T1.73T1.98T2.32T2.75T3.02T3.29T3.50T3.86T5.02T5.67T5.89T19.92T21.06T22.33T
Total Liabilities34.87B279.55B273.53B375.57B507.77B682.77B891.38B974.60B938.39B822.97B883.60B907.85B986.73B1.59T1.62T1.62T2.79T3.48T4.98T
Total Equity25.31B219.72B285.67B779.89B899.55B1.05T1.09T1.25T1.69T2.05T2.29T2.49T2.76T3.31T3.92T4.14T16.98T17.44T17.21T
Cash1.61B302.47M16.10B29.18B49.28B53.16B80.75B108.75B149.93B268.41B419.21B410.55B546.14B684.29B1.19T551.19B564.61B996.43B1.12T
Total Debt27.26B231.93B248.65B275.00B416.87B599.03B749.46B845.45B795.86B678.94B640.92B516.56B495.37B774.40B744.36B792.33B---
Net Debt25.66B231.63B232.55B245.82B367.59B545.87B668.71B736.70B645.94B410.54B221.71B106.01B-50.77B90.11B-443.97B241.15B1.31T1.17T2.57T

Cash Flow

Currency: KRW2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.61B46.79B44.95B33.60B62.76B20.97B137.08B145.16B77.57B250.89B485.98B364.79B473.99B350.75B911.16B863.53M537.16B901.87B646.05B
Investing Cash Flow-------229.38B-106.34B-166.94B-162.49B-245.10B-175.84B-251.44B-471.98B-355.83B----
Financing Cash Flow4.57B19.53B31.22B242.90B57.42B129.42B119.87B-11.32B130.43B28.67B-96.28B-198.14B-85.92B265.99B-69.28B-350.22B---
Capital Expenditure10.04B61.20B47.37B141.39B214.27B114.96B87.17B135.39B184.58B178.29B96.99B187.82B286.14B541.39B321.57B311.99B353.73B333.52B331.73B
Free Cash Flow-7.43B-14.42B-2.41B-107.79B-151.51B-93.99B49.91B9.77B-107.02B72.60B388.99B176.97B187.86B-190.65B589.59B-311.12B183.43B568.35B314.32B
Dividends Paid294.98M52.93B--8.69B11.52B2.59B68.40K714.23K--3.78M3.78M3.78M3.78M102.45B51.66B103.60B153.76B
FCF to OCF-284.88%-30.82%-5.36%-320.85%-241.40%-448.21%36.41%6.73%-137.97%28.94%80.04%48.51%39.63%-54.35%64.71%-36029.03%34.15%63.02%48.65%
Dividend Paid to FCF-3.97%-367.11%---5.74%-12.25%5.19%0.00%-0.00%--0.00%0.00%-0.00%0.00%-32.93%28.17%18.23%48.92%

Earnings

Report DateNov 15, 2010Mar 30, 2011Mar 30, 2012Aug 14, 2012May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 28, 2014Sep 3, 2014Nov 28, 2014Feb 17, 2015May 14, 2015Aug 4, 2015Nov 10, 2015Feb 16, 2016May 13, 2016Aug 12, 2016Nov 14, 2016Mar 9, 2017May 11, 2017Aug 11, 2017Nov 14, 2017Jan 19, 2018May 9, 2018Aug 8, 2018Nov 14, 2018Mar 18, 2019May 8, 2019Aug 14, 2019Nov 14, 2019Mar 19, 2020May 8, 2020Aug 14, 2020Nov 16, 2020Feb 22, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Feb 15, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 3, 2023May 12, 2023Aug 14, 2023Nov 14, 2023Feb 29, 2024May 16, 2024Aug 14, 2024Nov 14, 2024Feb 25, 2025May 15, 2025Aug 14, 2025Nov 14, 2025Mar 3, 2026May 7, 2026Aug 6, 2026Oct 29, 2026Feb 4, 2027
EPS Estimate217.52169.76271.35321.81------------198.56374.54330.98361.19444.25417.99282.34755.26734.83788.05673.98638.30507.72660.50514.11615.78724.06730.14707.031087.89912.62934.04851.26879.711344.96778.20737.91869.80870.18961.13956.79566.3829.87208.99753.80900.60617.04783.281070.531496.581036.511450.511653.732075.56
EPS Actual193.09190.89292.56256.72211.62229.23177.95-22.63111.54517.17111.8983.70-115.04447.04434.85318.3766.05545.30356.27380.83529.60686.93674.39798.32619.05622.78335.66268.68466.85464.43369.24599.69752.59828.601022.05740.361159.24752.27812.29845.19715.331111.981013.03503.001007.33901.801361.427.4094.19328.80361.071049.45484.43262.861436.192398.001576.001609.00--
Surprise-11.23%12.45%7.82%-20.23%-------------66.74%45.59%7.64%5.44%19.21%64.34%138.86%5.70%-15.76%-20.97%-50.20%-57.91%-8.05%-29.69%-28.18%-2.61%3.94%13.49%44.56%-31.95%27.02%-19.46%-4.58%-3.92%-46.81%42.89%37.28%-42.17%15.76%-6.17%42.29%-98.69%215.33%57.33%-52.10%16.53%-21.49%-66.44%34.16%60.23%52.05%10.93%--
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hours------Pre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap48.80T
Enterprise Value50.38T
Trailing P/E30.31
Forward P/E27.62
PEG Ratio0.84
Price / Sales9.96
Price / Book2.67
EPS6,912.14
Book Value78,513.44
Revenue (TTM)4.90T
Gross Profit (TTM)3.03T
EBITDA1.84T
Profit Margin32.18%
Operating Margin31.56%
Return on Equity9.11%
Return on Assets4.37%
Shares Outstanding228.02M
Shares Float158.74M
Beta0.23
Dividend Yield0.34%
Dividend Rate714.29
Payout Ratio12.79%

Dividends

20251×
714.29Dec 29, 2025
20241×
654.11Dec 27, 2024
20231×
436.07Dec 27, 2023
20221×
327.05Dec 28, 2022
20211×
628.95Dec 29, 2021
20121×
16.28Dec 27, 2012
20111×
73.14Dec 28, 2011
20101×
54.85Dec 29, 2010
20071×
36.57Dec 27, 2007
20061×
36.57Dec 27, 2006

Stock Splits

  • Jun 4, 20261.05:1
  • Jun 9, 20251.04:1
  • Dec 27, 20241.05:1
  • Dec 28, 20221.04:1
  • Dec 29, 20211.02:1
  • Dec 29, 20201.02:1
  • Dec 27, 20191.05:1
  • Dec 27, 20181.02:1
  • Dec 27, 20171.02:1
  • Dec 28, 20161.05:1
  • Dec 29, 20151.03:1
  • Dec 29, 20141.05:1
  • Dec 27, 20131.03:1
  • Mar 4, 20131:2
  • Dec 27, 20121.15:1
  • May 24, 20121.5:1